Klotho Neurosciences, Inc. Stock Price

NasdaqCM:KLTO Community·US$26.4m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

KLTO Share Price Performance

US$0.35

-0.12 (-25.62%)

US$0.35

-0.12 (-25.62%)

US$0.35

Sat, 27 Dec 25

Share Pricen/a

KLTO Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks

0 Rewards

View Full Analysis

Klotho Neurosciences, Inc. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -0.16
: 0%
: 0%
: 0%

View Full Analysis

About KLTO

Founded: n/a
Employees: 3
CEO: Joseph Sinkule
WebsiteView website: klothoneuro.com

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.